8-K: PROCEPT BioRobotics Q4 2025 Results & 2026 Guidance Update

PROCEPT BioRobotics reported strong Q4 2025 procedure volume and system sales, alongside a reset of 2026 revenue guidance due to strategic realignments.

Summary

• Total revenue for the fourth quarter of 2025 was $76.4 million, an increase of 12% compared to the prior year period.
• U.S. procedures reached approximately 12,200 in Q4 2025, an increase of approximately 69% year-over-year.
• The company sold 65 new systems in Q4 2025, marking its strongest capital quarter.
• U.S. handpieces sold were approximately 9,400 in Q4 2025, an increase of approximately 7% year-over-year.
• Handpiece average selling price increased 5% sequentially to $3,340 in Q4 2025.
• The U.S. install base grew 42% year-over-year to 718 systems as of December 31, 2025.
• International revenue was $9.8 million for Q4 2025, an increase of 25% compared to the prior year period.
• Gross margin for Q4 2025 was 61%, down from 64% in the prior year period, primarily due to lower-than-expected U.S. consumable revenue and a one-time field action cost.
• Operating expenses in Q4 2025 increased to $77.4 million from $63.4 million in the prior year period.
• Net loss for Q4 2025 was $29.8 million, compared to a loss of $18.9 million in the prior year period.
• Adjusted EBITDA loss for Q4 2025 was $19.0 million, compared to a loss of $10.3 million in the prior year period.
• Full year 2025 revenue was $308.1 million, an increase of 37% compared to the prior year.
• Full year 2025 gross margin improved to 64% from 61% in 2024.
• Full year 2025 net loss was $95.6 million, compared to $91.4 million in 2024.
• Full year 2025 Adjusted EBITDA loss improved to $50.2 million from $61.1 million in 2024.
• Cash, cash equivalents, and restricted cash totaled $289.5 million as of December 31, 2025.
• The company reset its full year 2026 revenue guidance to a range of $390 million to $410 million, representing 27% to 33% annual growth.
• Full year 2026 U.S. procedure growth is expected to be in the range of 39% to 48%.
• Full year 2026 gross margin is expected to be approximately 65%.
• Full year 2026 operating expenses are expected to be approximately $350 million.
• Full year 2026 adjusted EBITDA loss is projected to be in the range of $30 million to $17 million.
• First quarter 2026 total procedures are expected to be 12,000 to 12,800, representing 31% to 36% growth.
• First quarter 2026 total revenue is expected to be $79 million to $82 million, representing 14% to 19% growth.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While operational metrics like procedure volume and install base growth are strong, the widening losses in Q4 and the 'reset' of 2026 guidance (implying a downward adjustment from prior expectations) introduce caution. The strategic changes are positive long-term but create short-term headwinds.

Positives

• Achieved highest procedure volume to date with approximately 12,200 U.S. procedures in Q4 2025, a 69% increase year-over-year.
• Recorded strongest capital quarter by selling 65 new systems in Q4 2025.
• U.S. install base grew significantly by 42% year-over-year to 718 systems.
• Handpiece average selling price increased 5% sequentially to $3,340 in Q4 2025 due to a more disciplined pricing strategy.
• International revenue showed strong growth, increasing 25% year-over-year in Q4 2025.
• Full year 2025 revenue grew 37% to $308.1 million, driven by system placements and increased handpieces sold.
• Full year 2025 gross margin improved to 64% from 61% in 2024, attributed to improved overhead absorption and favorable revenue mix.
• Adjusted EBITDA loss improved for the full year 2025 to $50.2 million from $61.1 million in 2024.
• Strategic realignments of the commercial organization and establishment of a dedicated launch team are intended to drive durable procedure growth and reduce activation variability.
• Increased funding for the Water IV Prostate Cancer trial indicates continued investment in innovation and future growth opportunities.

Negatives

• Experienced a fourth quarter revenue shortfall due to reduced field inventory levels and the elimination of end-of-quarter purchasing incentives.
• Gross margin declined in Q4 2025 to 61% from 64% in the prior year, primarily due to lower-than-expected U.S. consumable revenue and a one-time cost associated with a voluntary field action.
• Operating expenses increased significantly in Q4 2025 to $77.4 million from $63.4 million, reflecting continued investment in commercial expansion and R&D.
• Net loss widened in Q4 2025 to $29.8 million from $18.9 million in the prior year period.
• Adjusted EBITDA loss widened in Q4 2025 to $19.0 million from $10.3 million in the prior year period.
• Cash and cash equivalents decreased from $333.7 million at December 31, 2024, to $286.5 million at December 31, 2025.
• The 2026 handpiece revenue guidance was reduced due to the decision to forecast handpiece unit sales and procedure volumes in close alignment, although this impact is partially offset by higher handpiece prices.
• Anticipates short-term disruption associated with the sales force realignment.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from anticipated results and expectations.
• Actual results and the timing of events could differ materially from those anticipated in forward-looking statements due to various risks and uncertainties.
• Risks and uncertainties are described more fully in the 'Risk Factors' section of the company's filings with the SEC, including its annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.
• All surgical treatments have inherent and associated side effects.

Future Outlook

The company expects full year 2026 revenue to be in the range of $390 million to $410 million, reflecting 27% to 33% growth, with U.S. procedure growth projected between 39% and 48%. Gross margin is anticipated to be approximately 65%, and Adjusted EBITDA loss is expected to narrow to between $30 million and $17 million. This guidance incorporates strategic realignments and a new handpiece pricing strategy, which are believed to be essential for achieving sustained high growth and establishing a favorable financial profile, despite short-term operational disruption.

Management Comments

• "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter." Larry Wood, Chief Executive Officer.
• "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commercial organization, established a dedicated launch team to reduce activation variability, and implemented a more disciplined handpiece pricing strategy." Larry Wood, Chief Executive Officer.
• "Furthermore, we successfully reduced field inventory levels and eliminated end-of-quarter purchasing incentives, which led to a fourth quarter revenue shortfall but improved handpiece average selling price by approximately 5%." Larry Wood, Chief Executive Officer.
• "Historically, handpiece unit sales exceeded procedure volumes by approximately 8% to 16%. Going forward, we expect handpiece unit sales and procedure volumes to be closely aligned." Larry Wood.
• "While annual U.S. procedure growth will be in the range of 39% to 48%, our decision to forecast procedure and handpiece volumes in close alignment has reduced our projected 2026 handpiece revenue guidance; however, this impact is meaningfully offset by higher handpiece prices of $3,500 per unit." Larry Wood.
• "Considering these factors, together with the short-term disruption associated with the sales force realignment, we are resetting our 2026 guidance to $390 to $410 million, representing annual growth of 27% to 33%." Larry Wood.
• "We believe these actions are essential to our long-term goals of sustained high growth and establishing a favorable financial profile." Larry Wood.

Industry Context

StockSavvy.ai notes that PROCEPT BioRobotics operates in the specialized and growing surgical robotics market, focusing on Benign Prostatic Hyperplasia (BPH) treatment. The company's emphasis on Aquablation therapy, particularly with its AI-Powered HYDROS Robotic System, positions it as an innovator within urology. The strategic realignments and focus on optimizing handpiece pricing suggest a move towards enhancing profitability and market efficiency, aligning with broader industry trends of leveraging technology for improved patient outcomes and sustainable business models in medical devices.

Comparison to Industry Standards

• The company's Aquablation therapy is highlighted for delivering effective, safe, and durable outcomes for BPH, independent of prostate size and shape or surgeon experience, which is a key competitive advantage in the BPH treatment landscape.
• The HYDROS Robotic System is noted as the only AI-Powered robotic technology that delivers Aquablation therapy, differentiating it from other robotic or non-robotic BPH solutions.
• PROCEPT BioRobotics has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, demonstrating a strong commitment to scientific validation and clinical efficacy, which is crucial for adoption in the medical device sector.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the guidance reset and widening losses, but could benefit from long-term strategic realignments and continued growth in procedures and install base.
• Employees may be impacted by the sales force realignment, though overall investment in commercial expansion and R&D suggests ongoing growth opportunities.
• Customers (urologists and hospitals) will benefit from continued innovation, such as increased funding for the Water IV Prostate Cancer trial and the expansion of the install base, improving access to Aquablation therapy.
• Patients suffering from BPH are expected to benefit from the continued development and expansion of Aquablation therapy, aiming for positive health outcomes.

Next Steps

• Host a conference call on February 25, 2026, to discuss the fourth quarter 2025 financial results.
• Host an in-person investor day event on February 26, 2026, at the NASDAQ Headquarters in New York City.
• Continue investment to support commercial expansion.
• Continue innovation across the BPH platform technology.
• Increase funding for the Water IV Prostate Cancer trial.
• Implement strategic realignments to sharpen focus on delivering durable procedure growth.
• Establish a dedicated launch team to reduce activation variability.
• Implement a more disciplined handpiece pricing strategy.

Key Dates

Recommendation

While PROCEPT BioRobotics demonstrates strong operational growth in procedures and install base, the widening net losses and adjusted EBITDA losses in Q4 2025, coupled with a 'reset' of 2026 revenue guidance (implying a downward adjustment from prior expectations due to strategic shifts and short-term disruption), suggest a period of transition. The strategic realignments and focus on higher average selling prices are positive for long-term profitability, but the immediate financial impact and guidance adjustment warrant a cautious 'Hold' stance until the effectiveness of these strategic changes on the financial profile becomes clearer.

Keywords

Surgical Robotics, Urology, BPH Treatment, Aquablation Therapy, PROCEPT BioRobotics, PRCT, Financial Results, Earnings, Revenue Guidance, Medical Devices, Robotic Surgery, Prostate Health